Comparison of overall survival between de novo and secondary acute lymphoblastic leukemia patients of different ages

The study focused on the survival rate in patients with acute lymphoblastic leukemia (ALL). A total of 8305 ALL patients undergoing chemotherapy from the SEER database. Included patients were divided into thede novo ALL group (n=7454) and sALL group (n=851). Results showed the decreased survival rate of ALL with aging. sALL patients (18-75 years) had poorer prognosis.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research